Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the IUPAC name "2-(5-{3-[6-benzoyl‑1‑propylnaphthalen‑2‑yloxy]propoxy}-1H-indol‑1‑yl)acetic acid". It belongs to the class of benzophenones and features an indole-acetic acid core linked via a propoxy chain to a substituted naphthalene. The compound has been referenced in chemical and pharmacological databases as an experimental agent, but there is no evidence of clinical development or approved therapeutic use. Some sources suggest it may act as a peroxisome proliferator activated receptor (PPAR) agonist, but this mechanism is not confirmed in primary literature or regulatory filings[1][2][8]. No information on its clinical indications, developer companies, or marketed products was found.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-{5-[3-(6-benzoyl-1-propylnaphthalen-2-yloxy)propoxy]indol-1-yl}ethanoic acid.